Some insight into the ability of JAK inhibitors to perform synergistically with currently available MM treatments, including IMiDs, has recently been gained by our group through in vitro and in vivo analyses of the preclinical anti-MM effects of another selective JAK1 inhibitor INCB052793 [21]. The gene discussed is JAK1; the disease is Miyoshi myopathy.